CytoDyn Inc.
CytoDyn Inc. (CYDY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cydy · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CytoDyn Inc.You CYDY | $404M | N/A | — | — |
 BioInvent International AB (publ) BOVNF | $436M | N/A | — | -$5.05 |
 Clinuvel Pharmaceuticals Limited CLVLF | $323M | 15.19x | -38.5% | $0.72 |
 Clinuvel Pharmaceuticals Limited CLVLY | $328M | 14.30x | -42.1% | $0.72 |
 Cellectis S.A. CMVLF | $251M | N/A | — | -$0.70 |
 Frontage Holdings Corporation FGHQF | $304M | 44.63x | +80.6% | $0.00 |
 Healios K.K. HLOSF | $291M | N/A | — | -$20.61 |
Industry Average 3 peers with valid PE | — | 24.71x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CytoDyn Inc. (CYDY) measures how much investors pay for each dollar of the company's trailing earnings. CYDY's current PE ratio of N/A is calculated by dividing its stock price of $0.30 by its TTM earnings per share of —.
Frequently asked questions
CYDY pe ratio · 6 questionsCYDY's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.30 and TTM EPS of —. Data sourced from Financial Modeling Prep via CYDY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CytoDyn Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09